Oxytrol OTC Success Depends On Driving Behavioral Changes
This article was originally published in The Tan Sheet
Executive Summary
Merck’s Oxytrol for Women could set the stage for other OTC switches indicated for chronic conditions, but the lifestyle changes recommended with the drug could be a hurdle. Oxytrol faces similar challenges to alli, another first-in-class switch with behavioral changes recommended.
You may also be interested in...
Oxytrol For Women Exclusivity Ends Not With Competition, But Label Warning Change
Private labeler Perrigo has eyed launching a generic since FDA approved the 3.9mg oxybutynin transdermal as a first-in-class OTC in 2013. Currently, though, Perrigo says it is "not a big product" and is talking about other prescription OAB products that could be approved for OTC.
With Generic Mucinex Delayed, Perrigo Will Need Alternatives To Drive Sales Growth
Perrigo hopes to ship store-brand Mucinex expectorant products in time for the next cough and cold season, but analysts are skeptical with several targets for the launch missed already. However, the firm can drive growth through mergers and acquisitions and Rx-to-OTC growth opportunities.
With Generic Mucinex Delayed, Perrigo Will Need Alternatives To Drive Sales Growth
Perrigo hopes to ship store-brand Mucinex expectorant products in time for the next cough and cold season, but analysts are skeptical with several targets for the launch missed already. However, the firm can drive growth through mergers and acquisitions and Rx-to-OTC growth opportunities.